Top 10 expected best-selling drugs of 2021,

A medication is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management. Here is the list of expected 10 best-selling drugs of 2021-

Rank	Brand	Manufacturer
1	Humira	AbbVie
2	Keytruda	Merck
3	Revlimid	BMS
4	Eliquis	BMS/Pfizer
5	Eylea	Bayer/Regeneron
6	Opdivo	BMS
7	Stelara	J&J
8	Biktarvy	Gilead
9	Imbruvica	AbbVie/J&J
10	Xarelto	Bayer/J&J

 

Humira:

HUMIRA is a prescription medicine known as a TNF-alpha blocker and used as recommended, HUMIRA targets and blocks TNF-alpha in your body, which plays an important role in the inflammation and permanent joint damage associated with moderate to severe rheumatoid arthritis. Humira drives the sale of Abbvie. The drug has been facing biosimilar competition in Europe, but the US market was primarily driving the sales. Nearly 80% of the Humira sales are being generated in the US, where the product will face biosimilar competition from 2023.

Keytruda:

Keytruda is used alone or with other drugs to treat certain types of breast cancer, skin cancer (squamous cell carcinoma of the skin, Merkel cell carcinoma, and melanoma), colorectal cancer, endometrial cancer, renal cell carcinoma (a type of kidney cancer), esophageal cancer, gastroesophageal junction cancer. Keytruda, a PD-L1 inhibitor, is expected to have almost twice the revenues of Opdivo, another PD-L1 inhibitor. The product is approved for nearly 15 indications in the US, and the sales are primarily driven because of the lung cancer indication. The product is contributing to almost 30% of Merck’s revenues.

Revlimid (Lenalidomide, sold under the trade name Revlimid):

Revlimid, is an oral cancer drug that is used for the treatment of multiple myeloma. It is part of a class of drugs called immunomodulatory drugs (IMiDs), which work against cancer cells partly by supporting the function of the immune system. BMS obtained Revlimid with the acquisition of Celgene. The product is expected to add $12.71 billion to BMS in 2021. However, the product will face generic competition in the US market from 2022. The company has recently settled patent litigation with Cipla.

Eliquis (Apixaban, sold under the brand name Eliquis):

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. Eliquis, a product indicated for preventing stroke/systemic embolism in patients with NVAF and treatment of DVT/PE, is anticipated to forth the best-selling product in 2021.

Eylea (Eylea is the brand name for aflibercept):

Eylea reduces leakage from blood vessels in your eyes, so it helps to reduce swelling in your macula. The drug may help to improve vision in people with diabetic macular edema, might become the fifth best-selling product in 2021. The product has higher sales than the Lucentis, a Roche product indicated for the same indications.

Opdivo (Nivolumab, sold under the brand name Opdivo):

Opdivo has been approved for patients with a specific type of lung cancer: metastatic squamous non-small cell lung cancer (NSCLC). About 85% of lung cancers are NSCLC, and 25-30% of those are squamous NSCLC. On May 20, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy. Opdivo retains 8^th position on the list.

Stelara (Ustekinumab, sold under the brand name Stelara):

STELARA is a prescription medicine used to treat adults 18 years and older with moderately to severely active Crohn's disease who have already taken other medicine that did not work well enough, or they could not tolerate it. Stelara is expected to retain 7^th position in best-selling drugs of 2021.

Biktarvy:

Biktarvy is an antiviral medicine that prevents human immunodeficiency virus (HIV) from multiplying in your body. Biktarvy is used to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). HIV product, Biktarvy expected to retain eight places on the list.

Imbruvica:

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lympocytic leukemia/small lymphocytic lymphoma). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Imbruvica retains 9^th position on the list.

Xarelto (Rivaroxaban, sold under the brand name Xarelto):

Xarelto is an anticoagulant medication used to treat and prevent blood clots. Specifically, it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. Xarelto retains 10^th position on the list.

Sale forecast of pharmaceutical drugs in 2021:

Brand	Review’s Forecast ($ Bn)	Evaluate Pharma Forecast ($ Bn)
Humira	19.96	20
Keytruda	16.83	16.8
Revlimid	12.71	12.7
Eliquis	10.54	10.5
Eylea	8.87	8.9
Opdivo	8.76	8.9
Stelara	8.44	8.4
Biktarvy	8.42	8.4
Imbruvica	7.61	7.6
Xarelto	7.6	7.6

• AbbVie
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Merck
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• BMS
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• BMS/Pfizer
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bayer/Regeneron
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• BMS
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• J&J
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Gilead
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• AbbVie/J&J
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bayer/J&J
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
4. Company Profiles

• AbbVie
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Merck
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• BMS
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• BMS/Pfizer
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bayer/Regeneron
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• BMS
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• J&J
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Gilead
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• AbbVie/J&J
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bayer/J&J
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

The Last Word

• • Future Impact
  • About Us
  • Contact